Literature DB >> 27030924

Assessment of treatment response in tuberculosis.

Neesha Rockwood1,2, Elsa du Bruyn2, Thomas Morris1, Robert J Wilkinson1,2,3.   

Abstract

Antibiotic treatment of tuberculosis has a duration of several months. There is significant variability of the host immune response and the pharmacokinetic-pharmacodynamic properties of Mycobacterium tuberculosis sub-populations at the site of disease. A limitation of sputum-based measures of treatment response may be sub-optimal detection and monitoring of Mycobacterium tuberculosis sub-populations. Potential biomarkers and surrogate endpoints should be benchmarked against hard clinical outcomes (failure/relapse/death) and may need tailoring to specific patient populations. Here, we assess the evidence supporting currently utilized and future potential host and pathogen-based models and biomarkers for monitoring treatment response in active and latent tuberculosis. Biomarkers for monitoring treatment response in extrapulmonary, pediatric and drug resistant tuberculosis are research priorities.

Entities:  

Keywords:  Tuberculosis; biomarkers; humans; therapeutics; treatment outcome

Mesh：

Substances：

Year:  2016        PMID： 27030924      PMCID： PMC4949330          DOI： 10.1586/17476348.2016.1166960

Source DB:  PubMed          Journal:  Expert Rev Respir Med        ISSN： 1747-6348            Impact factor:   3.772


  99 in total

1.  Inhibition of isoniazid-induced expression of Mycobacterium tuberculosis antigen 85 in sputum: potential surrogate marker in tuberculosis chemotherapy trials.

Authors:  R S Wallis; M Phillips; J L Johnson; L Teixeira; L M Rocha; E Maciel; L Rose; C Wells; M Palaci; R Dietze; K Eisenach; J J Ellner
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

2.  Resolution of the acute-phase response in West African patients receiving treatment for pulmonary tuberculosis.

Authors:  S D Lawn; J Obeng; J W Acheampong; G E Griffin
Journal:  Int J Tuberc Lung Dis       Date:  2000-04       Impact factor: 2.373

3.  Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment.

Authors:  Sven O Friedrich; Andrea Rachow; Elmar Saathoff; Kasha Singh; Chacha D Mangu; Rodney Dawson; Patrick Pj Phillips; Amour Venter; Anna Bateson; Catharina C Boehme; Norbert Heinrich; Robert D Hunt; Martin J Boeree; Alimuddin Zumla; Timothy D McHugh; Stephen H Gillespie; Andreas H Diacon; Michael Hoelscher
Journal:  Lancet Respir Med       Date:  2013-07-01       Impact factor: 30.700

Review 4.  The early bactericidal activity of antituberculosis drugs.

Authors:  Andreas H Diacon; Peter R Donald
Journal:  Expert Rev Anti Infect Ther       Date:  2014-01-06       Impact factor: 5.091

5.  Early and rapid microscopy-based diagnosis of true treatment failure and MDR-TB.

Authors:  A Hamid Salim; K J M Aung; M A Hossain; A Van Deun
Journal:  Int J Tuberc Lung Dis       Date:  2006-11       Impact factor: 2.373

6.  Radiological cavitation, sputum mycobacterial load and treatment response in pulmonary tuberculosis.

Authors:  F M R Perrin; N Woodward; P P J Phillips; T D McHugh; A J Nunn; M C I Lipman; S H Gillespie
Journal:  Int J Tuberc Lung Dis       Date:  2010-12       Impact factor: 2.373

7.  An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis.

Authors:  Matthew P R Berry; Christine M Graham; Finlay W McNab; Zhaohui Xu; Susannah A A Bloch; Tolu Oni; Katalin A Wilkinson; Romain Banchereau; Jason Skinner; Robert J Wilkinson; Charles Quinn; Derek Blankenship; Ranju Dhawan; John J Cush; Asuncion Mejias; Octavio Ramilo; Onn M Kon; Virginia Pascual; Jacques Banchereau; Damien Chaussabel; Anne O'Garra
Journal:  Nature       Date:  2010-08-19       Impact factor: 49.962

8.  Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies.

Authors:  Ekaterina V Kurbatova; J Peter Cegielski; Christian Lienhardt; Rattanawadee Akksilp; Jaime Bayona; Mercedes C Becerra; Janice Caoili; Carmen Contreras; Tracy Dalton; Manfred Danilovits; Olga V Demikhova; Julia Ershova; Victoria M Gammino; Irina Gelmanova; Charles M Heilig; Ruwen Jou; Boris Kazennyy; Salmaan Keshavjee; Hee Jin Kim; Kai Kliiman; Charlotte Kvasnovsky; Vaira Leimane; Carole D Mitnick; Imelda Quelapio; Vija Riekstina; Sarah E Smith; Thelma Tupasi; Martie van der Walt; Irina A Vasilyeva; Laura E Via; Piret Viiklepp; Grigory Volchenkov; Allison Taylor Walker; Melanie Wolfgang; Martin Yagui; Matteo Zignol
Journal:  Lancet Respir Med       Date:  2015-02-26       Impact factor: 30.700

9.  Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients.

Authors:  Mohideen S Jawahar; Vaithilingam V Banurekha; Chinnampedu N Paramasivan; Fathima Rahman; Rajeswari Ramachandran; Perumal Venkatesan; Rani Balasubramanian; Nagamiah Selvakumar; Chinnaiyan Ponnuraja; Allaudeen S Iliayas; Navaneethapandian P Gangadevi; Balambal Raman; Dhanaraj Baskaran; Santhanakrishnan R Kumar; Marimuthu M Kumar; Victor Mohan; Sudha Ganapathy; Vanaja Kumar; Geetha Shanmugam; Niruparani Charles; Murugesan R Sakthivel; Kannivelu Jagannath; Chockalingam Chandrasekar; Ramavaram T Parthasarathy; Paranji R Narayanan
Journal:  PLoS One       Date:  2013-07-03       Impact factor: 3.240

10.  Impact of HIV co-infection on plasma level of cytokines and chemokines of pulmonary tuberculosis patients.

Authors:  Adane Mihret; Markos Abebe; Yonas Bekele; Abraham Aseffa; Gerhard Walzl; Rawleigh Howe
Journal:  BMC Infect Dis       Date:  2014-03-04       Impact factor: 3.090
View more
  26 in total

1.  A Semimechanistic Model of the Bactericidal Activity of High-Dose Isoniazid against Multidrug-Resistant Tuberculosis: Results from a Randomized Clinical Trial.

Authors:  Kamunkhwala Gausi; Elisa H Ignatius; Xin Sun; Soyeon Kim; Laura Moran; Lubbe Wiesner; Florian von Groote-Bidlingmaier; Richard Hafner; Kathleen Donahue; Naadira Vanker; Susan L Rosenkranz; Susan Swindells; Andreas H Diacon; Eric L Nuermberger; Kelly E Dooley; Paolo Denti
Journal:  Am J Respir Crit Care Med       Date:  2021-12-01       Impact factor: 21.405

Review 2.  Omics Biomarkers for Monitoring Tuberculosis Treatment: A Mini-Review of Recent Insights and Future Approaches.

Authors:  Dian Ayu Eka Pitaloka; Mas Rizky Anggun A A Syamsunarno; Rizky Abdulah; Lidya Chaidir
Journal:  Infect Drug Resist       Date:  2022-05-28       Impact factor: 4.177

Review 3.  Tuberculosis Treatment Monitoring and Outcome Measures: New Interest and New Strategies.

Authors:  Jan Heyckendorf; Sophia B Georghiou; Nicole Frahm; Norbert Heinrich; Irina Kontsevaya; Maja Reimann; David Holtzman; Marjorie Imperial; Daniela M Cirillo; Stephen H Gillespie; Morten Ruhwald
Journal:  Clin Microbiol Rev       Date:  2022-03-21       Impact factor: 50.129

4.  A virtual host model of Mycobacterium tuberculosis infection identifies early immune events as predictive of infection outcomes.

Authors:  Louis R Joslyn; Jennifer J Linderman; Denise E Kirschner
Journal:  J Theor Biol       Date:  2022-01-31       Impact factor: 2.405

5.  IP-10 Kinetics in the First Week of Therapy are Strongly Associated with Bacteriological Confirmation of Tuberculosis Diagnosis in HIV-Infected Patients.

Authors:  Alberto L García-Basteiro; Edson Mambuque; Alice den Hertog; Belén Saavedra; Inocencia Cuamba; Laura Oliveras; Silvia Blanco; Helder Bulo; Joe Brew; Luis E Cuevas; Frank Cobelens; Augusto Nhabomba; Richard Anthony
Journal:  Sci Rep       Date:  2017-10-30       Impact factor: 4.379

6.  Discovery and Validation of a Six-Marker Serum Protein Signature for the Diagnosis of Active Pulmonary Tuberculosis.

Authors:  Mary A De Groote; David G Sterling; Thomas Hraha; Theresa M Russell; Louis S Green; Kirsten Wall; Stephan Kraemer; Rachel Ostroff; Nebojsa Janjic; Urs A Ochsner
Journal:  J Clin Microbiol       Date:  2017-08-09       Impact factor: 5.948

7.  Diagnosis and Management of Osteoarticular Tuberculosis: A Drastic Change in Mind Set Needed-It is Not Enough to Simply Diagnose TB.

Authors:  Vikas M Agashe; Camilla Rodrigues; Rajiv Soman; Anjali Shetty; R B Deshpande; Kanchan Ajbani; Jitendra Pingle; Mandar Agashe; Hitendra Patil; Sagar Raghuwanshi; Manit Gundavda; Raju Gite; Mithun Jakkan; Amit Mishra; Aditya Menon
Journal:  Indian J Orthop       Date:  2020-07-25       Impact factor: 1.251

8.  Bacterial load slopes represent biomarkers of tuberculosis therapy success, failure, and relapse.

Authors:  Gesham Magombedze; Jotam G Pasipanodya; Tawanda Gumbo
Journal:  Commun Biol       Date:  2021-06-02

Review 9.  Advancing our understanding of HIV co-infections and neurological disease using the humanized mouse.

Authors:  Janice J Endsley; Matthew B Huante; Kubra F Naqvi; Benjamin B Gelman; Mark A Endsley
Journal:  Retrovirology       Date:  2021-06-16       Impact factor: 4.602

10.  Identification of potential lipid biomarkers for active pulmonary tuberculosis using ultra-high-performance liquid chromatography-tandem mass spectrometry.

Authors:  Yu-Shuai Han; Jia-Xi Chen; Zhi-Bin Li; Jing Chen; Wen-Jing Yi; Huai Huang; Li-Liang Wei; Ting-Ting Jiang; Ji-Cheng Li
Journal:  Exp Biol Med (Maywood)       Date:  2020-11-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.